OncLive July 1, 2020
Maurie Markman, MD

Precision medicine should be seen as being synergistic―or at a minimum additive―to population medicine.

Perhaps no debate is more intense in all of clinical investigative medicine than the one on the relevance of focusing studies on population based versus molecular-based strategies. Certain academic commentators have even used the coronavirus disease 2019 (COVID-19) pandemic to highlight their arguments that the National Institutes of Health and other funding agencies should spend less on understanding disease entities at the molecular level and far more on illnesses affecting large populations. This never-ending argument misses the most critical point, which is the basic observation that these 2 approaches to human disease are complementary rather than in conflict or opposition.

To be clear,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Healthcare System, Pharma / Biotech, Population Health Mgmt, Precision Medicine, Provider
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Oncologist talks personalized medicine for pancreatic cancer
AI offers a step above genomic solutions
How Mayo Clinic is using real-world data to advance precision medicine
Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Share This Article